title: Myocardial and coronary effects of propofol in rabbits with compensated cardiac hypertrophy.
abstract: BACKGROUND
  Myocardial effects of propofol have been previously investigated but most studies have been performed in healthy hearts. This study compared the cardiac effects of propofol on isolated normal and hypertrophic rabbits hearts.
  
  
  METHODS
  The effects of propofol (10-1,000 microM) on myocardial contractility, relaxation, coronary flow and oxygen consumption were investigated in hearts from rabbits with pressure overload-induced left ventricular hypertrophy (LVH group, n = 20) after aortic abdominal banding and from sham-operated control rabbits (SHAM group, n = 10), using an isolated and erythrocyte-perfused heart model. In addition, to assess the myocardial and coronary effects of propofol in more severe LVH, hearts with a degree of hypertrophy greater than 140% were selected (severe LVH group, n = 7).
  
  
  RESULTS
  The cardiac hypertrophy model induced significant left ventricular hypertrophy (136+/-21%, P < 0.05). The pressure-volume relation showed normal systolic function but an altered diastolic compliance in hypertrophic hearts. Propofol only decreased myocardial contractility and relaxation at supratherapeutic concentrations (> or = 300 microM) in SHAM and LVH groups. The decrease in myocardial performances was not significantly different in SHAM and LVH groups. Propofol induced a significant increase in coronary blood flow which was not significantly different between groups. In severe LVH group, the degree of hypertrophy reached to 157+/-23%. Similarly, the effects of concentrations of propofol were not significantly different from the SHAM group.
  
  
  CONCLUSIONS
  Propofol only decreased myocardial function at supratherapeutic concentrations. The myocardial and coronary effects of propofol were not significantly modified in cardiac hypertrophy.
authors.affiliation: Department of Anesthesiology, Centre Hospitalier Universitaire La Milétrie, Poitiers, France.
authors.forename: A
authors.initials: A
authors.lastname: Ouattara
authors.forename: O
authors.initials: O
authors.lastname: Langeron
authors.forename: R
authors.initials: R
authors.lastname: Souktani
authors.forename: S
authors.initials: S
authors.lastname: Mouren
authors.forename: P
authors.initials: P
authors.lastname: Coriat
authors.forename: B
authors.initials: B
authors.lastname: Riou
mesh_terms: D018686:Anesthetics, Intravenous / Q000494:pharmacology*; D000818:Animals; D003326:Coronary Circulation / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects* / Q000502:physiology; D005260:Female; D017379:Hypertrophy, Left Ventricular / Q000503:physiopathology*; D010101:Oxygen Consumption / Q000187:drug effects; D015742:Propofol / Q000494:pharmacology*; D011817:Rabbits; D014664:Vasodilation / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D018686:Anesthetics, Intravenous; D015742:Propofol